centchroman has been researched along with Angiogenesis, Pathologic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Meeran, SM; Mondal, P; Natesh, J; Penta, D | 1 |
| Farhan, M; Kannan, A; Khan, S; Lakra, AD; Meeran, SM; Penta, D; Shukla, S; Sinha, S | 1 |
| Balapure, AK; Dewangan, J; Kaushik, S; Rath, SK | 1 |
3 other study(ies) available for centchroman and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Dietary Diindolylmethane Enhances the Therapeutic Effect of Centchroman in Breast Cancer by Inhibiting Neoangiogenesis.
Topics: Cell Line, Tumor; Cell Proliferation; Centchroman; Humans; Neovascularization, Pathologic; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2023 |
Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis.
Topics: Animals; beta Catenin; Breast Neoplasms; Centchroman; Estrogen Antagonists; Female; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Neuropeptides; p21-Activated Kinases; rac1 GTP-Binding Protein; Random Allocation; Signal Transduction | 2020 |
Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Apoptosis; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Centchroman; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MAP Kinase Signaling System; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |